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PERSPECTIVE OPEN
Four patients with a history of acute exacerbations of COPD:
implementing the CHEST/Canadian Thoracic Society
guidelines for preventing exacerbations
Ioanna Tsiligianni1,2, Donna Goodridge3, Darcy Marciniuk4, Sally Hull5 and Jean Bourbeau6
The American College of Chest Physicians and Canadian Thoracic Society have jointly produced evidence-based guidelines for the
prevention of exacerbations in chronic obstructive pulmonary disease (COPD). This educational article gives four perspectives on
how these guidelines apply to the practical management of people with COPD. A current smoker with frequent exacerbations will
benefit from support to quit, and from optimisation of his inhaled treatment. For a man with very severe COPD and multiple
co-morbidities living in a remote community, tele-health care may enable provision of multidisciplinary care. A woman who is
admitted for the third time in a year needs a structured assessment of her care with a view to stepping up pharmacological and
non-pharmacological treatment as required. The overlap between asthma and COPD challenges both diagnostic and management
strategies for a lady smoker with a history of asthma since childhood. Common threads in all these cases are the importance
of advising on smoking cessation, offering (and encouraging people to attend) pulmonary rehabilitation, and the importance of
self-management, including an action plan supported by multidisciplinary teams.
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CASE STUDY 1: A 63-YEAR-OLD MAN WITH MODERATE/
SEVERE COPD AND A CHEST INFECTION
A 63-year-old self-employed plumber makes a same-day appoint-
ment for another ‘chest infection’. He caught an upper respiratory
tract infection from his grandchildren 10 days ago, and he now
has a productive cough with green sputum, and his breath-
lessness and fatigue has forced him to take time off work.
He has visited his general practitioner with similar symptoms
two or three times every year in the last decade. A diagnosis of
COPD was confirmed 6 years ago, and he was started on a short-
acting β2-agonist. This helped with his day-to-day symptoms,
although recently the symptoms of breathlessness have been
interfering with his work and he has to pace himself to get
through the day. Recovering from exacerbations takes longer than
it used to—it is often 2 weeks before he is able to get back to
work—and he feels bad about letting down customers. He cannot
afford to retire, but is thinking about reducing his workload.
He last attended a COPD review 6 months ago when his FEV1
was 52% predicted. He was advised to stop smoking and given a
prescription for varenicline, but he relapsed after a few days and
did not return for the follow-up appointment. He attends each
year for his ‘flu vaccination’. His only other medication is an ACE
inhibitor for hypertension.
Managing the presenting problem. Is it a COPD exacerbation?
A COPD exacerbation is defined as ‘an acute event characterised
by a worsening of the patient’s respiratory symptoms that is
beyond normal day-to-day variation and leads to change in
medications’.1,2 The worsening symptoms are usually increased
dyspnoea, increased sputum volume and increased sputum
purulence.1,2 All these symptoms are present in our patient who
experiences an exacerbation triggered by a viral upper respiratory
tract infection—the most common cause of COPD exacerbations.
Apart from the management of the acute exacerbation that could
include antibiotics, oral steroids and increased use of short-acting
bronchodilators, special attention should be given to his on-going
treatment to prevent future exacerbations.2 Short-term use of
systemic corticosteroids and a course of antibiotics can shorten
recovery time, improve lung function (forced expiratory volume in
one second (FEV1)) and arterial hypoxaemia and reduce the risk of
early relapse, treatment failure and length of hospital stay.1,2
Short-acting inhaled β2-agonists with or without short-acting anti-
muscarinics are usually the preferred bronchodilators for the
treatment of an acute exacerbation.1
Reviewing his routine treatment
One of the concerns about this patient is that his COPD is
inadequately treated. The Global Initiative for Chronic Obstructive
Lung Disease (GOLD) suggests that COPD management be based
on a combined assessment of symptoms, GOLD classification of
airflow limitation, and exacerbation rate.1 The modified Medical
Research Council (mMRC) dyspnoea score3 or the COPD Assess-
ment Tool (CAT)4 could be used to evaluate the symptoms/health
status. History suggests that his breathlessness has begun to
interfere with his lifestyle, but this has not been formally asssessed
since the diagnosis 6 years ago. Therefore, one would like to be
certain that these elements are taken into consideration in future
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management by involving other members of the health care
team. The fact that he had two to three exacerbations per year
puts the patient into GOLD category C–D (see Figure 1) despite
the moderate airflow limitation.1,5 Our patient is only being
treated with short-acting bronchodilators; however, this is only
appropriate for patients who belong to category A. Treatment
options for patients in category C or D should include long-acting
muscarinic antagonists (LAMAs) or long-acting β2-agonists
(LABAs), which will not only improve his symptoms
but also help prevent future exacerbations.2 Used in combination
with LABA or LAMA, inhaled corticosteroids also contribute to
preventing exacerbations.2
Prevention of future exacerbations
Exacerbations should be prevented as they have a negative
impact on the quality of life; they adversely affect symptoms and
lung function, increase economic cost, increase mortality and
accelerate lung function decline.1,2 Figure 2 summarises the
recommendations and suggestions of the joint American College
of Chest Physicians and Canadian Thoracic Society (CHEST/CTS)
Guidelines for the prevention of exacerbations in COPD.2 The
grades of recommendation from the CHEST/CTS guidelines are
explained in Table 1.
Pharmacological approach
In patients with moderate-to-severe COPD, the use of LABA or
LAMA compared with placebo or short-acting bronchodilators is
recommended to prevent acute exacerbations (Grades 1B and 1A,
respectively).2,6,7 LAMAs are associated with a lower rate of
exacerbations compared with LABAs (Grade 1C).2,6 The inhaler
technique needs to be checked and a suitable device selected. If
our patient does not respond to optimizing inhaled medication
and continues to have two to three exacerbations per year, there
are additional options that offer pulmonary rehabilitation and
other forms of pharmacological therapy, such as a macrolide,
theophylline, phosphodieseterase (PDE4) inhibitor or N-acetylo-
cysteine/carbocysteine,2 although there is no information about
their relative effectiveness and the order in which they should be
prescribed. The choice of prescription should be guided by the
risk/benefit for a given individual, and drug availability and/or cost
within the health care system.
Non-pharmacological approach
A comprehensive patient-centred approach based on the chronic
care model could be of great value.2,8
This should include the following elements
● Vaccinations: the 23-valent pneumococcal vaccine and annual
influenza vaccine are suggested as part of the overall medical
management in patients with COPD.2 Although there is no clear
COPD-specific evidence for the pneumococcal vaccine and the
evidence is modest for influenza, the CHEST/CTS Guidelines
concur with advice of the World Health Organization (WHO)9
and national advisory bodies,10–12 and supports their use in
COPD patients who are at risk for serious infections.2
● Smoking cessation (including counselling and treatment) has
low evidence for preventing exacerbations (Grade 2C).2
However, the benefits from smoking cessation are outstanding
as it improves COPD prognosis, slows lung function decline and
improves the quality of life and symptoms.1,2,13,14 Our patient
has struggled to quit in the past; assessing current readiness to
quit, and encouraging and supporting a future attempt is a
priority in his care.
● Pulmonary rehabilitation (based on exercise training, education
and behaviour change) in people with moderate-to-very-severe
COPD, provided within 4 weeks of an exacerbation, can prevent
acute exacerbations (Grade 1C).2 Pulmonary rehabilitation is
also an effective strategy to improve symptoms, the quality of
life and exercise tolerance,15,16 and our patient should be
encouraged to attend a course.
● Self-management education with a written action plan and
supported by case management providing regular direct access
to a health care specialist reduces hospitalisations and prevents
severe acute exacerbations (Grade 2C).2 Some patients with
good professional support can have an emergency course of
steroids and antibiotics to start at the onset of an exacerbation
in accordance with their plan.
Finally, close follow-up is needed for our patient as he was
inadequately treated, relapsed from smoking cessation after a few
days despite varenicline, and missed his follow-up appointment.
A more alert health care team may have been able to identify
these issues, avoid his relapse and take a timely approach to
introducing additional measures to prevent his recurrent acute
exacerbations.
CASE STUDY 2: A 74-YEAR-OLD MAN WITH VERY SEVERE
COPD LIVING ALONE IN A REMOTE COMMUNITY
A 74-year-old man has a routine telephone consultation with the
respiratory team. He has very severe COPD (his FEV1 2 years ago
was 24% of predicted) and he copes with the help of his daughter
who lives in the same remote community. He quit smoking the
previous year after an admission to the hospital 50 miles away,
which he found very stressful. He and his family managed another
four exacerbations at home with courses of steroids and
antibiotics, which he commenced in accordance with a self-
management plan provided by the respiratory team.
His usual therapy consists of regular long-acting β2-agonist/
inhaled steroid combination and a long-acting anti-muscarinic.
He has a number of other health problems, including coronary
heart disease and osteoarthritis and, in recent times, his daughter
Patient 
category C
High risk
few symptoms
GOLD
Exacerbations ≥2/year
or ≥ 1 admission
CAT score
mMRC
Patient 
category D
High risk
many symptoms
GOLD
Exacerbations ≥2/year
or ≥1 admission
CAT score ≥10
mMRC ≥2
Patient 
category A
Low risk
few symptoms
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Exacerbations ≤1/year
CAT score
mMRC
Patient 
category B
Low risk
many symptoms
GOLD
Exacerbations ≤1/year
CAT score ≥10
mMRC ≥2
3–4 3–4
<10
0–1
1–2 1–2
<10
0–1
Figure 1. The four categories of COPD based on assessment of
symptoms and future risk of exacerbations (adapted by Gruffydd-
Jones,5 from the Global Strategy for Diagnosis, Management and
Prevention of COPD).1 CAT, COPD Assessment Tool; COPD, chronic
obstructive pulmonary disease; mMRC, modified Medical Research
Council Dyspnoea Scale.
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has become concerned that he is becoming forgetful. He manages
at home by himself, steadfastly refusing social help and adamant
that he does not want to move from the home he has lived in for
55 years.
This is a common clinical scenario, and a number of
important issues require attention, with a view to optimising the
management of this 74-year-old man suffering from COPD. He has
very severe obstruction, is experiencing frequent acute flare-ups,
is dependent and isolated and has a number of co-morbidities. To
work towards preventing future exacerbations in this patient, a
comprehensive plan addressing key medical and self-care issues
needs to be developed that accounts for his particular context.
Optimising medical management
According to the CHEST/CTS Guidelines for prevention of acute
exacerbations of COPD,2 this patient should receive an annual
influenza vaccination and may benefit from a 23-valent pneumo-
coccal vaccine (Grades 1B and 2C, respectively). Influenza infection is
associated with greater risk of mortality in COPD, as well as
increased risk of hospitalisation and disease progression.1 A
diagnosis of COPD also increases the risk for pneumococcal disease
and related complications, with hospitalisation rates for patients
with COPD being higher than that in the general population.10,17
Although existing evidence does not support the use of this vaccine
specifically to prevent exacerbations of COPD,1 administration of the
23-valent pneumococcal vaccine is recommended as a component
of overall medical management.9–12
Long-term oxygen therapy has been demonstrated to improve
survival in people with chronic hypoxaemia;18 it would be helpful
to obtain oxygen saturation levels and consider whether
long-term oxygen therapy would be of benefit to this patient.
Even though this patient is on effective medications, further
optimisation of pharmacologic therapy should be undertaken,
including reviewing administration technique for the different
inhaler devices.19 Maintenance PDE4 inhibitors, such as roflumilast
or theophyllines, long-term macrolides (i.e., azithromycin) or oral
N-acetylcysteine are potential considerations. Each of these
therapeutic options has demonstrated efficacy in preventing
future acute exacerbations, although they should be used with
caution in this frail elderly man.2 This patient would benefit from a
review of co-morbidities, including a chest X-ray, electro-
cardiogram, memory assessment and blood tests including
haemoglobin, glucose, thyroid and renal function assessments.
Pulmonary rehabilitation, supported self-management and
tele-health care
Pulmonary rehabilitation for patients who have recently experi-
enced an exacerbation of COPD (initiated o4 weeks following the
Patient with COPD
(greater than 40 years of age, previous or current smoker, post bronchodilator FEV1/FVC <0.70)
At risk for acute exacerbation of COPD (AECOPD)
e.g., acute event that requires antibiotic and/or systemic corticosteroids
(moderate: at home, doctor’s office or ER; severe: in hospital)
PICO 2: Pharmacological inhaled therapies PICO 3: Pharmacological oral therapiesPICO 1: Non-pharmacological therapies
Recommended
-Annual influenza
 vaccine
-Pulmonary
 rehabilitation
 (AECOPD 
 ≤4 wks)
-SM education
 and case
 management
 with monthly
 follow-up
Not suggested
-Pulmonary
 rehabilitation
 (AECOPD >4 wks)
-Education or
 case management
 alone
-SM education
 with action plan
 but without case
 management
Recommended
-LABA vs. placebo 
-LAMA vs. placebo,
LABA or SAMA
-LABA and LAMA
 vs. placebo
-ICS (with LABA) vs.
 placebo, LABA or
 ICS alone 
Suggested
-SAMA + SABA vs.
 SABA
-SAMA + LABA vs.
 LABA
-SAMA vs. SABA
-LABA vs. SAMA
-LAMA/ICS/LABA vs.
 placebo
Suggested
-Long-term macrolides
-N-acetylcysteine
-Carbocysteine
-Systemic
 corticosteroids to
 prevent AECOPD in
 the 30 days after
 initial event
-PDE4 inhibitors
-Theophyllines
Not recommended
-Systemic
corticosteroids in the
first 6 months
following the initial
AECOPD
-Statins
Suggested
-Pneumococcal
 vaccine
-Smoking
 cessation
-SM education
 and action plan
 and case
 management
-Telemonitoring
Figure 2. Decision tree for prevention of acute exacerbations of COPD (reproduced with permission from the CHEST/CTS Guidelines for the
prevention of exacerbations in COPD).2 This decision tree for prevention of acute exacerbations of COPD is arranged according to three key
clinical questions using the PICO format: non-pharmacologic therapies, inhaled therapies and oral therapies. The wording used is
‘Recommended or Not recommended’ when the evidence was strong (Level 1) or ‘Suggested or Not suggested’ when the evidence was weak
(Level 2). CHEST/CTS, American College of Chest Physicians and Canadian Thoracic Society; COPD, chronic obstructive pulmonary disease;
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; LABA, long-acting β-agonist; LAMA, long-acting muscarinic
antagonist; ICS, inhaled corticosteroids; SAMA, short-acting muscarinic antagonist; SABA, short-acting β-agonist; SM, self-management.
Table 1. Summary of the grading system used in the CHEST/CTS guidelines for preventing exacerbations of COPD
Strength of recommendation Strength of evidence Balance of benefits versus risk Implication for clinicians
1—Strong recommendation A—High quality
B—Moderate
quality
C—Low quality
Benefits clearly outweigh risks and
burdens (or vice versa)
Strong recommendation, applies to most patients in most
circumstances
May change if higher quality evidence becomes available
2—Weak recommendation A—High quality
B—Moderate
quality
C—Low quality
Benefits closely balanced with
risks and burden
Weak recommendation, best action may differ depending
on circumstances
Other alternatives may be equally reasonable
Abbreviations: CHEST/CTS, American College of Chest Physicians and Canadian Thoracic Society; COPD, chronic obstructive pulmonary disease.
Adapted from Guyatt et al.49
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exacerbation) has been demonstrated to prevent subsequent
exacerbations (Grade 1C).2 Existing evidence suggests that
pulmonary rehabilitation does not reduce future exacerbations
when the index exacerbation has occurred more than 4 weeks
earlier;2 however, its usefulness is evident in other important
patient-centred outcomes such as improved activity, walking
distance and quality of life, as well as by reduced shortness of
breath. It would be appropriate to discuss this and enable our
patient to enrol in pulmonary rehabilitation.
The patient’s access to pulmonary rehabilitation in his remote
location, however, is likely to be limited. Several reports have
noted that only one to two percent of people with COPD are able
to access pulmonary rehabilitation programmes within Canada,20
the United States21 and the United Kingdom.22 Alternatives to
hospital-based pulmonary rehabilitation programmes, such as
home-based programmes or programmes offered via tele-health,
may be options for this patient.23 Home-based pulmonary
rehabilitation programmes have been found to improve exercise
tolerance, symptom burden and quality of life.24–27 Outcomes of a
pulmonary rehabilitation programme offered via tele-health have
also been found to be comparable to those of a hospital-based
programme,28 and may be worth exploring.
Written self-management (action) plans, together with educa-
tion and case management, are suggested in the CHEST/CTS
guidelines as a strategy to reduce hospitalisation and emergency
department visits attributable to exacerbations of COPD (Grade
2B).2 Our patient has an existing action plan, which has enabled
him and his family to manage some exacerbations at home.
Although the patient has likely had some education on COPD and
its management in the past, on-going reinforcement of key
principles may be helpful in preventing future exacerbations.
The self-management plan should be reviewed regularly to
ensure the advice remains current. The patient’s ability to use the
self-management plan safely also needs to be assessed, given his
daughter’s recent observation of forgetfulness and his living
alone. Cognitive impairment is being increasingly recognised as a
significant co-morbidity of COPD.29,30 Patients who were awaiting
discharge from hospital following an exacerbation of COPD were
found to perform significantly worse on a range of cognitive
functional measures than a matched group with stable COPD, a
finding that persisted 3 months later.29 Cognitive impairment may
contribute independently to the risk for future exacerbations by
increasing the likelihood of incorrect inhaler device use and failure
to adhere to recommended treatments.29
Given that this patient resides in a remote location, access to
case management services that assist in preventing future
exacerbations may be difficult or impossible to arrange. Although
there is currently insufficient evidence that in general the use of
telemonitoring contributes to the prevention of exacerbations of
COPD,2 tele-health care for this remotely located patient has
potential to allow for case management at a distance, with
minimal risk to the patient. Further study is needed to address this
potential benefit.
Assessing for and managing frailty
Recognising this patient’s co-morbid diagnoses of coronary heart
disease and osteoarthritis, careful assessment of functional and
self-care abilities would be appropriate. Almost 60% of older
adults with COPD meet the criteria for frailty.31 Frailty is defined as
a dynamic state associated with decline of physiologic reserves in
multiple systems and inability to respond to stressful insults.32
Frailty is associated with an increased risk for institutionalisation
and mortality.33,34 Given the complex needs of those who are frail,
screening this patient for frailty would constitute patient-centred
and cost-effective care. Frailty assessment tools, such as the
seven-point Clinical Frailty Index,35 may provide structure to this
assessment.
Admission to a hospital 50 miles away from our patient’s home
last year for an exacerbation was stressful. Since his hospitalisa-
tion, this patient has experienced four additional exacerbations
that have been managed at home in his remote community. It
would be appropriate to explore the patient’s treatment wishes
and determine whether the patient has chosen to refuse further
hospitalisations. Our patient’s risk of dying is significant, with risk
factors increasing the risk of short-term mortality following an
exacerbation of COPD (GOLD Stage 4, age, male sex, confusion).36
Mortality rates between 22 and 36% have been documented
in the first and second years, respectively, following an
exacerbation,37,38 which also increase with the frequency and
severity of hospitalisations.39
Our patient has refused social help and does not want to be
relocated from his home. Ageing in their own home is a key goal
of many older adults.40,41 Efforts to ensure that adequate
resources to support the patient are available (and to support
the daughter who is currently providing a lot of his care) will form
an important part of the plan of care.
CASE STUDY 3: A 62-YEAR-OLD WOMAN WITH SEVERE COPD
ADMITTED WITH AN EXACERBATION
A 62-year-old lady is admitted for the third time this year with an
acute exacerbation of her severe COPD. Her FEV1 was 35%
predicted at the recent outpatient visit. She retired from her job as
a shop assistant 5 years ago because of her breathlessness and
now devotes her time to her grandchildren who ‘exhaust her’ but
give her a lot of pleasure.
She quit smoking 5 years ago. Over the years, her medication
has increased, as nothing seemed to relieve her uncomfortable
breathlessness, and, in addition to inhaled long-acting β2-agonist/
inhaled steroid combination and a long-acting anti-muscarinic,
she is taking theophylline and carbocysteine, although she is not
convinced of their beneficial effect. Oral steroid courses help her
dyspnoea and she has taken at least six courses this year: she has
an action plan and keeps an emergency supply of medication
at home.
A secondary care perspective on the management strategy for this
woman
Acute exacerbations of COPD have serious negative consequences
for health care systems and patients. The risk of future events and
complications, such as hospital admission and poor patient
outcomes (disability and reduced health status), can be improved
through a combination of non-pharmacological and pharmaco-
logical therapies.2
Evaluation of the patient, risk assessment and adherence to
medication
The essential first step in the management of this lady (as for any
patient) includes a detailed medical evaluation. Our patient has a
well-established diagnosis of COPD with severe airflow obstruc-
tion (GOLD grade 3), significant breathlessness that resulted in her
retiring from her job, and recurrent exacerbations. She does not
have significant co-morbidity, although this requires to be
confirmed. Further to the medical evaluation, it is important to
assess her actual disease management (medication and proper
use) as well as making sure she has adopted a healthy lifestyle
(smoking cessation, physical activities and exercise). Does she live
in a smoke-free environment? Effect of and evidence for smoking
cessation in the prevention of acute exacerbations of COPD is low,
but evidence exists for a reduction in cough and phlegm after
smoking cessation and less lung function decline upon sustained
cessation. With respect to the medication, never assume that it is
taken as prescribed. When asking the patient, use open questions
such as ‘I would like to hear how you take your medication on a
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typical day?’ instead of ‘Did you take the medication as
prescribed’. Open questions tend to elicit more useful and
pertinent information, and invite collaboration. Asking the patient
to demonstrate her inhalation technique shows you the way she
uses her different inhalation devices.
Optimising the pharmacological therapy
The second step is to assess whether the patient is on optimal
treatment to prevent exacerbations. In other words, can we do
better helping the patient manage her disease and improving her
well-being. As in the previous cases, vaccination, in particular,
annual administration of the influenza vaccine, should be
prescribed for this lady. We should evaluate other alternatives of
pharmacological therapy that could improve symptoms, prevent
exacerbations and reduce the use of repeated systemic corticos-
teroids with their important adverse effects (such as osteoporosis,
cataracts, diabetes). Prescribing a PDE4 inhibitor (Grade 2A) or a
long-term macrolide (Grade 2A) once a day would be a
consideration for this lady.2 As there is no superiority trial
comparing these two medications, our preference will be based
on potential side effects, as well as cost and access to treatment.
For PDE4 inhibitors, there are limited data on supplemental
effectiveness in patients with COPD and chronic bronchitis
concurrently using inhaled therapies, and they potentially have
side effects such as diarrhoea, nausea, headache and weight loss.
The side effects tend to diminish over time, but some patients
may have to discontinue the therapy. Long-term macrolides have
been studied in COPD patients already treated with inhaled
therapies and shown to be effective, although clinicians need to
consider in their individual patients the potential for harm, such as
prolongation of the QT interval, hearing loss and bacterial
resistance. Furthermore, the duration (beyond 1 year) and exact
dosage of macrolide therapy (for example, once daily versus three
times per week) are unknown.
Making non-pharmacological therapy an essential part of the
management
The third step, often neglected in the management of COPD
patients, is non-pharmacological therapy. For this lady, we suggest
self-management education with a written action plan and case
management to improve how she deals with exacerbations (Grade
2B).2 The expectation will not be to reduce exacerbations but to
prevent emergency department visits and hospital admissions.
However, despite general evidence of efficacy,42 not all self-
management interventions have been shown to be effective or to
benefit all COPD patients43,44 (some have been shown to be
potentially harmful44). The effectiveness of any complex interven-
tion such as self-management in COPD critically depends on the
health care professionals who deliver the intervention, as well on
the patient and the health care system. The patient may not have
the motivation or desire to change or to commit to an intensive
programme. The individual patient’s needs, preferences and
personal goals should inform the design of any intervention with
a behavioural component. For this lady, it is essential to apply
integrated disease management and to refer the patient to a
pulmonary rehabilitation programme. Pulmonary rehabilitation
has high value, including reducing the risk for hospitalisation in
COPD patients with recent exacerbations (Grade 1C).2 The most
important benefits our patient can expect from participating in
structured supervised exercise within pulmonary rehabilitation are
improved health status, exercise tolerance and a reduction in
dyspnoea (Grade 1A).2,15 Pulmonary rehabilitation programmes
provide clinicians with an opportunity to deliver education and
self-management skills to patients with COPD, and are well
established as a means of enhancing standard therapy to control
and alleviate symptoms, optimise functional capacity and improve
health-related quality of life.
CASE STUDY 4: A 52-YEAR-OLD LADY WITH MODERATE
COPD—AND POSSIBLY ASTHMA
A 52-year-old lady attends to discuss her COPD and specifically
the problem she is having with exacerbations and time ‘off sick’.
She is a heavy smoker, and her progressively deteriorating lung
function suggests that she has moderate COPD, although she also
has a history of childhood asthma, and had allergic rhinitis as a
teenager. Recent spirometry showed a typical COPD flow-volume
loop, although she had some reversibility (250 ml and 20%) with a
post-bronchodilator FEV1 of 60% predicted.
She has a sedentary office job and, although she is breathless
on exertion, this generally does not interfere with her lifestyle. The
relatively frequent exacerbations are more troublesome. They are
usually triggered by an upper respiratory infection and can take a
couple of weeks to recover. She has had three exacerbations this
winter, and as a result her employer is not happy with her sickness
absence record and has asked her to seek advice from her general
practitioner.
She has a short-acting β2-agonist, although she rarely uses it
except during exacerbations. In the past, she has used an inhaled
steroid, but stopped that some time ago as she was not convinced
it was helping.
It is a welcome opportunity when a patient comes to discuss
her COPD with a particular issue to address. With a history of
childhood asthma, and serial COPD lung function tests, she has
probably been offered many components of good primary care
for COPD, but has not yet fully engaged with her management.
We know that ~ 40% of people with COPD continue to smoke, and
many are intermittent users of inhaled medications.45 It is easy to
ignore breathlessness when both job and lifestyle are sedentary.
Understanding her diagnosis and setting goals
Her readiness to engage can be supported by a move to
structured collaborative care, enabling the patient to have the
knowledge, resources and support to make the necessary
changes. Much of this can be done by the primary care COPD
team, including the pharmacist. Regular recall to maintain
engagement is essential.
Figure 3. The COPD value pyramid (developed by the London
Respiratory Network with The London School of Economics and
reproduced with permission from the London Respiratory Team
report 2013).48 This 'value' pyramid reflects what we currently know
about the cost per QALY of some of the commonest interventions in
COPD. It was devised as a tool for health care organisations to use to
promote audit and to ensure adequate commissioning of non-
pharmacological interventions. COPD, chronic obstructive pulmon-
ary disease; LABA, long-acting β-agonist; QALY, quality-adjusted life-
year.
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The combination of childhood asthma, rhinitis and a long
history of smoking requires diagnostic review. This might include
serial peak flows over 2 weeks to look for variability, and a chest
X-ray, if not done recently, to rule out lung cancer as a reason for
recent exacerbations. Her spirometry suggests moderate COPD,1,46
but she also has some reversibility, not enough to place her in the
asthma camp but, combined with her past medical history, being
enough to explore an asthma COPD overlap syndrome. This is
important to consider as it may guide decisions on inhaled
medication, and there is evidence that lung function deteriorates
faster in this group.47 It is estimated that up to 20% of patients
have overlap diagnoses, although the exact prevalence depends
on the definition.48
Reducing the frequency of exacerbations
Exacerbations in COPD are debilitating, often trigger hospital
admission and hasten a progressive decline in pulmonary
function.2 Written information on interventions that can slow
down the course of COPD and reduce the frequency and impact
of exacerbations will help to support progressive changes in
management.
Smoking cessation
Few people are unaware that cessation of smoking is the key
intervention for COPD. Reducing further decline in lung function
will slow down the severity of exacerbations. Finding a smoking
cessation programme that suits her working life, exploring
previous attempts at cessation, offering pharmacotherapy and a
non-judgemental approach to further attempts at stopping are
crucial.
Immunisations
Many, but not all, exacerbations of COPD are triggered by viral
upper respiratory tract infections. Annual flu immunisation is a
part of regular COPD care and reduces exacerbations and
hospitalisation when flu is circulating (Grade 1B). Pneumococcal
immunisation should be offered, although evidence for reducing
exacerbations is weak; those with COPD will be at greater risk for
pneumococcal infection.2
Pulmonary rehabilitation
Pulmonary rehabilitation improves symptoms, quality of life and
reduces hospital admission.49 It is most efficacious in patients who
are symptomatic (MRC dyspnoea scale 3 and above) and in terms
of reducing exacerbations is most effective when delivered early
after an exacerbation (Grade 1C).2 The major hurdle is encoura-
ging patients to attend, with most programmes showing an
attrition rate of 30% before the first appointment, and high rates
of non-completion.45,50 Effective programmes that maintain the
gains from aerobic exercise are more cost-effective than some of
the inhaled medications in use (see Figure 3).50
Medication
Inhaled medication is likely to improve our patient’s breath-
lessness and contribute to a reduction in exacerbation frequency.
Currently, she uses only a short-acting β2-agonist. One wonders if
she has a spacer? How much of the medicine is reaching her
lungs? Repeated observation and training in inhaler use is
essential if patients are to benefit from expensive medications.
With her history of asthma and evidence of some reversibility,
the best choice of regular medication may be a combination of
inhaled corticosteroid and a LABA. Guidelines suggest the asthma
component in asthma COPD overlap syndrome should be the
initial treatment target,48 and a LABA alone should be avoided.
Warn about oral thrush, and the increased risk for pneumonia.46 If
she chooses not to use an inhaled steroid, then a trial of a LAMA is
indicated. Both drugs reduce exacerbation rates.2,51
Finally, ensuring early treatment of exacerbations speeds up
recovery.52 Prescribe rescue medication (a 5–7-day course of oral
steroids and antibiotic) to be started when symptomatic, and
encourage attendance at a post-exacerbation review.
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